Renal Cancer - Results from #1640

Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). February 8, 2022

Update on the treatment of metastatic renal cell carcinoma. February 8, 2022

Zero ischemia laparoscopic microwave ablation assisted enucleation vs. laparoscopic partial nephrectomy in clinical T1a renal tumor: a randomized clinical trial. February 7, 2022

The changing trends of image-guided biopsy of small renal masses before intervention-an analysis of European multinational prospective EuRECA registry. February 7, 2022

Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. February 4, 2022

Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. February 4, 2022

Improving accuracy, reliability, and efficiency of the RENAL nephrometry score with 3D reconstructed virtual imaging. February 3, 2022

Decreased CDKL2 Expression in Clear Cell Renal Cell Carcinoma Predicts Worse Overall Survival. February 3, 2022

The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. February 2, 2022

Decreased Expression of ACADSB Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. February 2, 2022

The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma. February 1, 2022

Utilizing head-mounted eye trackers to analyze patterns and decision-making strategies of 3D virtual modelling platform (IRIS™) during preoperative planning for renal cancer surgeries. February 1, 2022

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. January 31, 2022

Prognostic and Clinicopathological Correlations of Pretreatment Prognostic Nutritional Index in Renal Cell Carcinoma: A Meta-Analysis. January 31, 2022

MicroRNA-155-5p targets NR3C2 to promote malignant progression of clear cell renal cell carcinoma. January 28, 2022

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. January 28, 2022

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery January 27, 2022

Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma. January 27, 2022

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. January 27, 2022

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. January 26, 2022

Page 83 of 456